<DOC>
	<DOCNO>NCT00361868</DOCNO>
	<brief_summary>Under condition first-line drug treatment antidiabetic drug na√Øve/drug free patient type 2 diabetes mellitus dyslipidemia , show : - efficacy fix combination ( FC ) fenofibrate metformin glycemic control inferior rosiglitazone efficacy FC fenofibrate metformin triglyceride control superior rosiglitazone .</brief_summary>
	<brief_title>Fenofibrate Metformin Fixed Combination v Rosiglitazone - FAME ROSI</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Glucose Metabolism Disorders</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Patient Type 2 diabetes mellitus dyslipidemia inadequately control lifestyle modification . Type 1 diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Treatment Dyslipidemia Type 2 Diabetes Mellitus</keyword>
</DOC>